BioXcel Therapeutics (BTAI) Research & Development (2017 - 2026)

BioXcel Therapeutics' Research & Development history runs 10 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• On a quarterly basis, Research & Development fell 35.11% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $28.7 million, a 21.47% increase from a year earlier, with the FY2025 full-year figure at $30.3 million, down 0.6% from the prior year.
• Research & Development fell to $3.0 million in Q1 2026 per BTAI's latest filing, from $6.7 million in the prior quarter.
• Across five years, Research & Development topped out at $32.5 million in Q4 2022 and bottomed at $3.0 million in Q1 2026.
• The 5-year median for Research & Development is $10.3 million (2025), against an average of $14.1 million.
• Across the five-year window, Research & Development jumped 159.15% in 2022 and sank 74.0% in 2024, its largest moves.
• Year by year, Research & Development stood at $32.5 million in 2022, then sank by 69.4% to $9.9 million in 2023, then tumbled by 40.6% to $5.9 million in 2024, then increased by 13.56% to $6.7 million in 2025, then plunged by 55.9% to $3.0 million in 2026.
• Per Business Quant, the three latest BTAI Research & Development figures stand at $3.0 million (Q1 2026), $6.7 million (Q4 2025), and $8.7 million (Q3 2025).